{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T01:19:02Z","timestamp":1766711942255,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.clbc.2018.03.004","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T13:39:19Z","timestamp":1520516359000},"page":"e781-e787","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cabazitaxel Plus Lapatinib as Therapy for HER2+ Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding Study"],"prefix":"10.1016","volume":"18","author":[{"given":"Denise A.","family":"Yardley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lowell L.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick J.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail L.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mythili","family":"Shastry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey","family":"Finney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura M.","family":"DeBusk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Hainsworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2018.03.004_bib1","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/annonc\/mdl064","article-title":"International Breast Cancer Study Group (IBCSG). Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)","volume":"17","author":"Pestalozzi","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2018.03.004_bib2","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1002\/cncr.27581","article-title":"Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network","volume":"15","author":"Lin","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2018.03.004_bib3","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1002\/cncr.11436","article-title":"Central nervous system metastases in women who receive trastuzumab based therapy for metastatic breast carcinoma","volume":"97","author":"Bendell","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2018.03.004_bib4","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1158\/1078-0432.CCR-10-2962","article-title":"Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER","volume":"17","author":"Brufsky","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2018.03.004_bib5","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2018.03.004_bib6","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11060-013-1083-9","article-title":"The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer","volume":"112","author":"Sperduto","year":"2013","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.clbc.2018.03.004_bib7","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/bjc.2011.597","article-title":"Brain metastases free survival differs between breast cancer subtypes","volume":"106","author":"Berghoff","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2018.03.004_bib8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10549-012-2243-x","article-title":"Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype","volume":"136","author":"Arvold","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2018.03.004_bib9","first-page":"307","article-title":"Breast cancer brain metastases: new directions in systemic therapy","volume":"7","author":"Lin","year":"2013","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.clbc.2018.03.004_bib10","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1158\/1078-0432.CCR-06-2478","article-title":"Brain metastases: the HER2 paradigm","volume":"13","author":"Lin","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2018.03.004_bib11","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/S1470-2045(15)00332-0","article-title":"Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial","volume":"16","author":"Perez","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2018.03.004_bib12","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2007.12.3588","article-title":"Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor-positive breast cancer","volume":"26","author":"Lin","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2018.03.004_bib13","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2018.03.004_bib14","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-08-1080","article-title":"Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer","volume":"15","author":"Lin","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2018.03.004_bib15","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdn171","article-title":"A\u00a0multicenter phase II study of XRP6258 administered as 1-h IV infusion every 3 weeks in taxane-resistant metastatic breast cancer patients","volume":"19","author":"Pivot","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2018.03.004_bib16","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.ejca.2011.01.001","article-title":"A\u00a0multicenter dose escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I\/II study","volume":"47","author":"Villanueva","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2018.03.004_bib17","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/cmdc.200600308","article-title":"Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes","volume":"2","author":"Galletti","year":"2007","journal-title":"ChemMedChem"},{"key":"10.1016\/j.clbc.2018.03.004_bib18","first-page":"303","article-title":"In\u00a0vitro activity of TXD258 in chemotherapeutic resistant tumor cell lines","volume":"41","author":"Aller","year":"2000","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1016\/j.clbc.2018.03.004_bib19","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1172\/JCI0215451","article-title":"Transport of paclitaxel (Taxol) across the blood-brain barrier in\u00a0vitro and in\u00a0vivo","volume":"110","author":"Fellner","year":"2002","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clbc.2018.03.004_bib20","first-page":"215","article-title":"Pharmocokinetics of a new taxoid 14C-TXD258, in blood, plasma and brain of mouse, rat and dog","volume":"41","author":"Archimbaud","year":"2000","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1016\/j.clbc.2018.03.004_bib21","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/sj.bjp.0705150","article-title":"Nonlinear accumulation in the brain of new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats","volume":"138","author":"Cisternino","year":"2003","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clbc.2018.03.004_bib22","first-page":"301","article-title":"Efficacy evaluation of TXD258, a taxoid compound, against orthotopic and subcutaneous glioblastomas","volume":"41","author":"Dykes","year":"2000","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1016\/j.clbc.2018.03.004_bib23","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"Wolff","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2018.03.004_bib24","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1200\/JCO.2016.72.1076","article-title":"Phase III study comparing a reduced dose of cabazitaxel (20 mg\/m2) and the currently approved dose (25 mg\/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA","volume":"35","author":"Eisenberger","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2018.03.004_bib25","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(12)70432-1","article-title":"Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study","volume":"14","author":"Bachelot","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2018.03.004_bib26","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1158\/1078-0432.CCR-16-1496","article-title":"Phase I study of ONT-380, a HER2 inhibitor, in patients with HER2+ advanced solid tumors, with an expansion cohort in HER2+ metastatic breast cancer","volume":"23","author":"Moulder-Thompson","year":"2017","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820917306687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820917306687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:17:01Z","timestamp":1761513421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820917306687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1526820917306687"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2018.03.004","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cabazitaxel Plus Lapatinib as Therapy for HER2+ Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2018.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}